Innovent to Present Multiple Clinical and Preclinical Results of Mazdutide and Next-Generation Obesity & Metabolic Pipeline at the 2026 ADA Scientific Sessions
On May 12, 2026, it was announced that Innovent Biologics, Inc. ("Innovent") based in San Francisco and Suzhou, China, is a leading biopharmaceutical company specializing in the development, manufacturing, and distribution of top-tier medications. Innovent is listed on the Hong Kong Stock Exchange under the symbol 01801. The company focuses on producing high-quality drugs for oncology, cardiovascular, and metabolic treatments.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments